Bioceltech Therapeutics Beijing

Bioceltech Therapeutics is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of next-generation immunotherapy for solid tumors. The company leverages two core technology platforms: a high-efficiency mRNA-LNP delivery system and an off-the-shelf CAR-NK cell therapy platform. Their lead programs focus on targeting difficult-to-treat solid malignancies such as liver, pancreatic, and gastric cancers by enhancing the persistence and infiltration of immune cells. Bioceltech aims to overcome the limitations of current CAR-T therapies in solid tumors through its innovative 'off-the-shelf' approach and mRNA-mediated immune modulation.